INmune Bio Forms Scientific Advisory Board to Accelerate CORDStrom Platform Expansion — INmune Bio Inc.

Event summary

INmune Bio established a Scientific Advisory Board (SAB) to support late-stage development of Ebstrocel for RDEB and expand its CORDStrom platform.
The SAB includes four internationally recognized experts in MSC biology, clinical translation, manufacturing, and rare pediatric skin diseases.
Professor Mark Lowdell will chair the SAB, which will advise on regulatory strategy, trial design, mechanism-of-action studies, and new indications.
CORDStrom is designed to address MSC challenges with proprietary donor screening, pooling, and expansion for consistent, scalable cell medicine.
The platform aims for regulatory filings in the UK (2026), EU (2027), and U.S. (early 2027).

The big picture

INmune Bio's formation of a Scientific Advisory Board underscores its strategic shift toward late-stage development and regulatory filings for its CORDStrom platform. The move aligns with broader industry trends in precision medicine, where specialized advisory boards are increasingly critical for navigating complex regulatory landscapes and accelerating clinical trials. With planned submissions in the UK (2026), EU (2027), and U.S. (early 2027), INmune Bio is positioning itself to capitalize on the growing demand for advanced cell therapies targeting rare and inflammatory diseases.

What we're watching

Regulatory Strategy: How the SAB's guidance will shape Ebstrocel's regulatory submissions and approval timelines in key markets.
Clinical Development: Whether the SAB can accelerate Phase 3 trial design and patient selection for RDEB and other indications.
Platform Expansion: The pace at which INmune Bio can identify and develop new disease-specific applications for the CORDStrom platform.